Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alpha Wealth Funds - The Insiders Fund Portfolio Manager | “GE HealthCare operates as a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. The company received FDA clearance for its MIM Contour ProtégéAI+ 2.0 software, heavily advancing its AI-driven radiation therapy planning capabilities. Progression into Phase 2/3 of its LUMINA trial for a manganese-based MRI contrast agent under FDA Fast Track designation has further de-risked its future pharmaceutical diagnostics pipeline. The introduction of new Allia upgrade pathways aimed at retrofitting existing clinical interventional suites has boosted the company's outlook on recurring services and equipment modernization revenue. Strong position in imaging and ultrasound markets. I believe the market will rotate into a broader sector other than AI infrastructure names. Healthcare in general should be a beneficiary and in particular GE Healthcare as it has been a laggard and significant insider buying may indicate management confidence.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Fenimore Dividend Focus Strategy John Fox | “We initiated a stake in GE HealthCare Technologies (GEHC). GEHC was spun off from General Electric and provides imaging products such as MRIs, CT scanners, and ultrasound equipment to healthcare facilities. Their large equipment generates significant recurring revenue through service and maintenance contracts. New AI features have the potential to drive significant revenue growth as customers adopt software upgrades in their existing equipment. BSD Analysis: GE HealthCare combines a defensive installed base with emerging growth vectors from AI-enabled imaging and diagnostic software. Recurring service revenue provides stability, while new product cycles in MR, CT, and ultrasound support mid-single to high-single-digit growth. Valuation remains reasonable relative to peers given improving margins, deleveraging, and optionality from software attach rates.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
